Shandong Sinobioway Biomedicine Co Ltd (002581) - Total Assets

Latest as of September 2025: CN¥2.21 Billion CNY ≈ $324.07 Million USD

Based on the latest financial reports, Shandong Sinobioway Biomedicine Co Ltd (002581) holds total assets worth CN¥2.21 Billion CNY (≈ $324.07 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.

Shandong Sinobioway Biomedicine Co Ltd - Total Assets Trend (2007–2024)

This chart illustrates how Shandong Sinobioway Biomedicine Co Ltd's total assets have evolved over time, based on quarterly financial data. Also see 002581 market cap overview for the company's overall valuation and market capitalisation.

Shandong Sinobioway Biomedicine Co Ltd - Asset Composition Analysis

Current Asset Composition (December 2024)

Shandong Sinobioway Biomedicine Co Ltd's total assets of CN¥2.21 Billion consist of 34.0% current assets and 66.0% non-current assets. Review Shandong Sinobioway Biomedicine Co Ltd total liabilities to assess the company's total debt and financial obligations.

Asset Category Amount (CNY) % of Total Assets
Cash & Equivalents CN¥0.00 23.1%
Accounts Receivable CN¥144.53 Million 6.6%
Inventory CN¥79.64 Million 3.6%
Property, Plant & Equipment CN¥0.00 0.0%
Intangible Assets CN¥93.47 Million 4.3%
Goodwill CN¥0.00 0.0%

Asset Composition Trend (2007–2024)

This chart illustrates how Shandong Sinobioway Biomedicine Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest Shandong Sinobioway Biomedicine Co Ltd stock price today for real-time trading data and today's change.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Shandong Sinobioway Biomedicine Co Ltd's current assets represent 34.0% of total assets in 2024, a decrease from 58.9% in 2007.
  • Cash Position: Cash and equivalents constituted 23.1% of total assets in 2024, up from 20.2% in 2007.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 1.0% in 2007.
  • Asset Diversification: The largest asset category is accounts receivable at 6.6% of total assets.

Shandong Sinobioway Biomedicine Co Ltd Competitors by Total Assets

Key competitors of Shandong Sinobioway Biomedicine Co Ltd based on total assets are shown below.

Company Country Total Assets
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
Sweden Skr81.26 Billion
Yunnan Baiyao Group Co Ltd
SHE:000538
China CN¥53.34 Billion
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
China CN¥5.17 Billion
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
USA $15.42 Trillion
Harbin Gloria Pharmaceuticals
SHE:002437
China CN¥3.14 Billion
Jiuzhitang Co Ltd
SHE:000989
China CN¥5.73 Billion
Renhe Pharmacy Co Ltd
SHE:000650
China CN¥7.93 Billion
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
China CN¥6.74 Billion

Shandong Sinobioway Biomedicine Co Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 4.20 11.18 3.70
Quick Ratio 3.52 9.93 3.36
Cash Ratio 0.00 0.00 0.00
Working Capital CN¥597.91 Million CN¥657.33 Million CN¥559.30 Million

Shandong Sinobioway Biomedicine Co Ltd - Advanced Valuation Insights

This section examines the relationship between Shandong Sinobioway Biomedicine Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 2.58
Latest Market Cap to Assets Ratio 0.23
Asset Growth Rate (YoY) -6.0%
Total Assets CN¥2.20 Billion
Market Capitalization $501.04 Million USD

Valuation Analysis

Below Book Valuation: The market values Shandong Sinobioway Biomedicine Co Ltd's assets below their book value (0.23x), which may indicate investor concerns about asset quality or future growth.

Significant Asset Reduction: Shandong Sinobioway Biomedicine Co Ltd's assets decreased by 6.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for Shandong Sinobioway Biomedicine Co Ltd (2007–2024)

The table below shows the annual total assets of Shandong Sinobioway Biomedicine Co Ltd from 2007 to 2024.

Year Total Assets Change
2024-12-31 CN¥2.20 Billion
≈ $321.33 Million
-6.04%
2023-12-31 CN¥2.34 Billion
≈ $342.00 Million
-18.22%
2022-12-31 CN¥2.86 Billion
≈ $418.20 Million
+3.69%
2021-12-31 CN¥2.76 Billion
≈ $403.30 Million
+12.72%
2020-12-31 CN¥2.44 Billion
≈ $357.77 Million
-28.38%
2019-12-31 CN¥3.41 Billion
≈ $499.57 Million
-20.48%
2018-12-31 CN¥4.29 Billion
≈ $628.26 Million
+7.41%
2017-12-31 CN¥4.00 Billion
≈ $584.91 Million
+48.73%
2016-12-31 CN¥2.69 Billion
≈ $393.27 Million
+11.25%
2015-12-31 CN¥2.42 Billion
≈ $353.50 Million
+213.95%
2014-12-31 CN¥769.49 Million
≈ $112.60 Million
-0.56%
2013-12-31 CN¥773.80 Million
≈ $113.23 Million
+6.14%
2012-12-31 CN¥729.02 Million
≈ $106.68 Million
+5.63%
2011-12-31 CN¥690.19 Million
≈ $101.00 Million
+229.16%
2010-12-31 CN¥209.68 Million
≈ $30.68 Million
+27.12%
2009-12-31 CN¥164.95 Million
≈ $24.14 Million
+14.92%
2008-12-31 CN¥143.53 Million
≈ $21.00 Million
+50.23%
2007-12-31 CN¥95.54 Million
≈ $13.98 Million
--

About Shandong Sinobioway Biomedicine Co Ltd

SHE:002581 China Drug Manufacturers - Specialty & Generic
Market Cap
$501.04 Million
CN¥3.42 Billion CNY
Market Cap Rank
#12343 Global
#3600 in China
Share Price
CN¥5.19
Change (1 day)
+1.76%
52-Week Range
CN¥3.10 - CN¥8.75
All Time High
CN¥39.86
About

Shandong Sinobioway Biomedicine Co., Ltd. engages in the pharmaceutical manufacturing industry in China. The company is involved in the chemical raw materials, chemical product manufacturing, and biopharmaceutical manufacturing; production and sales of medicines. It also offers operating chemical products, such as trimethyl ester and triethyl ester. The company was founded in 2000 and is based in… Read more